by admin | Sep 23, 2026 | Case, Fitness to Practise, GPhC
The client, MD, approached me several months ago after becoming the subject of two non-clinical investigations by the General Pharmaceutical Council (GPhC). Having received a referral and undertaken considerable research into representation options, he was clear about...
by admin | Sep 23, 2026 | GDC, GMC, GOsC, GPhC, HCPC, NMC, SWE
Overview Whistleblowing remains an important route into fitness to practise investigations across UK healthcare professions. Recent data shows increases in whistleblowing disclosures across medicine, dentistry and nursing. Concerns most commonly relate to conduct,...
by admin | Sep 7, 2026 | GMC
Overview Recent MPTS data highlights clear patterns in the types of behaviours and circumstances most likely to result in adverse tribunal outcomes. Criminal convictions, dishonesty, sexual misconduct and drug‑related misconduct continue to dominate the most serious...
by admin | Aug 14, 2026 | GDC, GMC, GOsC, GPhC, HCPC, NMC, SWE
Overview The High Court refused the NMC’s application to extend an interim order, criticising aspects of the regulator’s handling of the fitness to practise case. The judgement reinforces that an interim order cannot become a substitute for progressing a...
by admin | Aug 14, 2026 | GDC
Overview GDC launches consultation on new guidance shaping early fitness to practise decision‑making. Clearer criteria for assessing conduct, health and communication concerns. More structured thresholds for escalation — especially in behavioural cases. Faster triage...
